Takeda Halts Development Of Actos Combination Product
Japanese drug maker will focus on other projects in diabetes after ending fixed-dose combination of Actos with its angiotensin receptor blocker azilsartan.
Japanese drug maker will focus on other projects in diabetes after ending fixed-dose combination of Actos with its angiotensin receptor blocker azilsartan.